Tag Archives: New Drug Applications

Biopharma Innovation in Trouble?

Next year it will cost $2.2 million to submit an NDA or biologics license application (BLA) for FDA review, and $1 million for a supplement with clinical data, generally to support new indications or expanded labeling. Review of a new biosimilar application that carries clinical data will be just as costly. While a $2 million […]
Posted in Biotech, FDA, Guest Blog | Also tagged , , , | Leave a comment
  • Categories

  • Meta